Liquidia Corporation
LQDA
주식 순위
#4426
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating... Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.
주가
$38.75
마지막 동기화: 2026-10-21
시가총액
$3.47B
변동 (1일)
6.60%
변동 (1년)
73.46%
국가
US
거래 Liquidia Corporation (LQDA)
카테고리
Healthcare
Liquidia Corporation (LQDA)의 주가 이력
최고 종가: $30.60 (2026-10-01 기준)
최저 종가: $11.01 (2018-07-01 기준)
최저 종가: $11.01 (2018-07-01 기준)
Liquidia Corporation의 주가 이력 (2018 ~ 2026)
연간 주가 성과
| 연도 | 성과 |
|---|---|
| 2026 (TTM) | 42.98% |
| 2025 | 204.28% |
| 2024 | 26.82% |
| 2023 | 47.93% |
| 2022 | 37.03% |
| 2021 | 48.32% |
| 2020 | -24.23% |
| 2019 | -82.68% |
| 2018 | 0.00% |
유사 기업 또는 경쟁사의 주가
| 회사 | 주가 | 변동률 1년% | 국가 |
|---|---|---|---|
| $62.20 | 68.82% |
US
|
|
| $46.29 | 37.83% |
SE
|
|
| $171.04 | 23.67% |
FR
|
|
| $116.39 | 58.03% |
US
|
|
| $59.46 | -0.57% |
IT
|
